Therapeutics/Diagnostics News

WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.

WASHINGTON — “Even at short intervals,” an intermittent low-calorie, plant-based diet may improve inflammation and response to medical therapy among patients with moderately to severely active ulcerative colitis, according to a presenter.

WASHINGTON — Provider recommendation was a major influencer for colonoscopy screening for young adults at average risk for colorectal cancer, especially non-Hispanic Black patients, according to data presented at Digestive Disease Week.

WASHINGTON — In a Healio video exclusive, Saqr Alsakarneh, MD, MSc, describes “significant disparities” in race, ethnicity and sex among participants enrolled clinical trials for liver transplantation in the U.S.

WASHINGTON — Surveillance colonoscopy after polyp removal was associated with a 77% relative reduction in risk for colorectal cancer, although more research is needed to determine its effect on mortality risk, according to study results.

WASHINGTON — The Primary Obesity Surgery Endoluminal 2.0 procedure is a “safe, effective and durable option” for weight loss and improvement in obesity-related conditions, according to a presenter.

WASHINGTON — Seladelpar use led to “rapid, marked and sustained improvement” in markers of cholestasis and liver injury among patients with primary biliary cholangitis, according to interim results of the ongoing, phase 3 ASSURE study.

In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.